CARIBOU BIOSCIENCES INC (CRBU) Fundamental Analysis & Valuation

NASDAQ:CRBU • US1420381089

Current stock price

1.95 USD
+0.09 (+4.84%)
At close:
1.93 USD
-0.02 (-1.03%)
After Hours:

This CRBU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CRBU Profitability Analysis

1.1 Basic Checks

  • In the past year CRBU has reported negative net income.
  • In the past year CRBU has reported a negative cash flow from operations.
  • CRBU had negative earnings in each of the past 5 years.
  • In the past 5 years CRBU always reported negative operating cash flow.
CRBU Yearly Net Income VS EBIT VS OCF VS FCFCRBU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • CRBU's Return On Assets of -84.47% is on the low side compared to the rest of the industry. CRBU is outperformed by 70.21% of its industry peers.
  • CRBU has a worse Return On Equity (-121.24%) than 60.35% of its industry peers.
Industry RankSector Rank
ROA -84.47%
ROE -121.24%
ROIC N/A
ROA(3y)-51.89%
ROA(5y)-39.48%
ROE(3y)-69.3%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
CRBU Yearly ROA, ROE, ROICCRBU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRBU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBU Yearly Profit, Operating, Gross MarginsCRBU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CRBU Health Analysis

2.1 Basic Checks

  • CRBU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CRBU has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CRBU has been increased compared to 5 years ago.
  • CRBU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRBU Yearly Shares OutstandingCRBU Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CRBU Yearly Total Debt VS Total AssetsCRBU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -4.32, we must say that CRBU is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -4.32, CRBU is in line with its industry, outperforming 40.04% of the companies in the same industry.
  • CRBU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.32
ROIC/WACCN/A
WACC9.21%
CRBU Yearly LT Debt VS Equity VS FCFCRBU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 5.71 indicates that CRBU has no problem at all paying its short term obligations.
  • CRBU has a Current ratio of 5.71. This is in the better half of the industry: CRBU outperforms 60.35% of its industry peers.
  • CRBU has a Quick Ratio of 5.71. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 5.71, CRBU is in the better half of the industry, outperforming 60.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.71
Quick Ratio 5.71
CRBU Yearly Current Assets VS Current LiabilitesCRBU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CRBU Growth Analysis

3.1 Past

  • CRBU shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.64%.
  • CRBU shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.66%.
  • CRBU shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.02% yearly.
EPS 1Y (TTM)3.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.21%
Revenue 1Y (TTM)11.66%
Revenue growth 3Y-6.95%
Revenue growth 5Y-2.02%
Sales Q2Q%89.74%

3.2 Future

  • CRBU is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.36% yearly.
  • CRBU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 86.25% yearly.
EPS Next Y13.8%
EPS Next 2Y7.58%
EPS Next 3Y-10.79%
EPS Next 5Y13.36%
Revenue Next Year14.6%
Revenue Next 2Y12.75%
Revenue Next 3Y41.33%
Revenue Next 5Y86.25%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRBU Yearly Revenue VS EstimatesCRBU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B
CRBU Yearly EPS VS EstimatesCRBU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. CRBU Valuation Analysis

4.1 Price/Earnings Ratio

  • CRBU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CRBU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBU Price Earnings VS Forward Price EarningsCRBU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBU Per share dataCRBU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

  • CRBU's earnings are expected to decrease with -10.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y-10.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRBU Dividend Analysis

5.1 Amount

  • CRBU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRBU Fundamentals: All Metrics, Ratios and Statistics

CARIBOU BIOSCIENCES INC

NASDAQ:CRBU (4/8/2026, 8:25:04 PM)

After market: 1.93 -0.02 (-1.03%)

1.95

+0.09 (+4.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-04
Inst Owners39.16%
Inst Owner Change0%
Ins Owners4.72%
Ins Owner Change19.43%
Market Cap188.45M
Revenue(TTM)11.16M
Net Income(TTM)-148.13M
Analysts85.33
Price Target11.56 (492.82%)
Short Float %8.1%
Short Ratio5.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.91%
Min EPS beat(2)11.45%
Max EPS beat(2)18.38%
EPS beat(4)3
Avg EPS beat(4)-2.63%
Min EPS beat(4)-45.06%
Max EPS beat(4)18.38%
EPS beat(8)6
Avg EPS beat(8)1.48%
EPS beat(12)9
Avg EPS beat(12)7.66%
EPS beat(16)12
Avg EPS beat(16)6.22%
Revenue beat(2)1
Avg Revenue beat(2)14.84%
Min Revenue beat(2)-23.49%
Max Revenue beat(2)53.17%
Revenue beat(4)3
Avg Revenue beat(4)16.89%
Min Revenue beat(4)-23.49%
Max Revenue beat(4)53.17%
Revenue beat(8)4
Avg Revenue beat(8)2.78%
Revenue beat(12)7
Avg Revenue beat(12)55.27%
Revenue beat(16)9
Avg Revenue beat(16)43.36%
PT rev (1m)2%
PT rev (3m)1.87%
EPS NQ rev (1m)3.68%
EPS NQ rev (3m)3.68%
EPS NY rev (1m)0%
EPS NY rev (3m)6.03%
Revenue NQ rev (1m)-15.43%
Revenue NQ rev (3m)-15.43%
Revenue NY rev (1m)8.77%
Revenue NY rev (3m)10.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.89
P/FCF N/A
P/OCF N/A
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-1.59
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0.12
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -84.47%
ROE -121.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.89%
ROA(5y)-39.48%
ROE(3y)-69.3%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.28%
Cap/Sales 12.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.71
Quick Ratio 5.71
Altman-Z -4.32
F-Score4
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)163.67%
Cap/Depr(5y)221.1%
Cap/Sales(3y)31.56%
Cap/Sales(5y)32.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.21%
EPS Next Y13.8%
EPS Next 2Y7.58%
EPS Next 3Y-10.79%
EPS Next 5Y13.36%
Revenue 1Y (TTM)11.66%
Revenue growth 3Y-6.95%
Revenue growth 5Y-2.02%
Sales Q2Q%89.74%
Revenue Next Year14.6%
Revenue Next 2Y12.75%
Revenue Next 3Y41.33%
Revenue Next 5Y86.25%
EBIT growth 1Y18.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.69%
OCF growth 3YN/A
OCF growth 5YN/A

CARIBOU BIOSCIENCES INC / CRBU Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CARIBOU BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to CRBU.


What is the valuation status for CRBU stock?

ChartMill assigns a valuation rating of 0 / 10 to CARIBOU BIOSCIENCES INC (CRBU). This can be considered as Overvalued.


What is the profitability of CRBU stock?

CARIBOU BIOSCIENCES INC (CRBU) has a profitability rating of 0 / 10.


What is the financial health of CARIBOU BIOSCIENCES INC (CRBU) stock?

The financial health rating of CARIBOU BIOSCIENCES INC (CRBU) is 6 / 10.